clinical trial · NCT04712097
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Hoffmann-La Roche·phase3·active not recruiting·n = 478
Relapsed or Refractory Follicular LymphomaMosunetuzumabLenalidomideRituximabTociluzumab
brief summary
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
started
Oct 27, 2021
primary completion
May 31, 2026
completion
Dec 31, 2029
last updated
Feb 4, 2026
official title
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol